The PE Ratio as of November 2024 (TTM) for Genelux Corporation (GNLX) is -3.23

According to Genelux Corporation’s latest financial reports and current stock price. The company's current PE Ratio is -3.23. This represents a change of -74.65% compared to the average of -12.74 of the last 4 quarters.

Genelux Corporation (GNLX) Historical PE Ratio (quarterly & annually)

How has GNLX PE Ratio performed in the past?

The mean historical PE Ratio of Genelux Corporation over the last ten years is -14.30. The current -3.23 PE Ratio has changed 2.16% with respect to the historical average. Over the past ten years (40 quarters), GNLX's PE Ratio was at its highest in in the September 2022 quarter at 9.80. The PE Ratio was at its lowest in in the June 2023 quarter at -36.33.

Genelux Corporation (GNLX) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Genelux Corporation PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Genelux Corporation (GNLX) Average PE Ratio

How has GNLX PE Ratio performed in the past?

The current PE Ratio of Genelux Corporation (GNLX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Genelux Corporation (GNLX) PE Ratio vs. Peers

How is GNLX’s PE Ratio compared to its peers?

Genelux Corporation’s PE Ratio is less than Comera Life Sciences Holdings, Inc. (-0.00), greater than Dyadic International, Inc. (-3.97), less than Cingulate Inc. (-1.18), greater than Monopar Therapeutics Inc. (-8.34), greater than Terns Pharmaceuticals, Inc. (-5.51), greater than Day One Biopharmaceuticals, Inc. (-17.12), less than Acumen Pharmaceuticals, Inc. (-2.73), less than Amylyx Pharmaceuticals, Inc. (-2.34), greater than MoonLake Immunotherapeutics (-53.23), greater than Monte Rosa Therapeutics, Inc. (-4.83), greater than NewAmsterdam Pharma Company N.V. (-7.40), less than Inventiva S.A. (-1.12), greater than Cullinan Oncology, Inc. (-6.16), greater than Compass Therapeutics, Inc. (-5.11), greater than Larimar Therapeutics, Inc. (-7.46), less than Immuneering Corporation (-0.98), greater than Centessa Pharmaceuticals plc (-11.03), greater than Celcuity Inc. (-7.15), less than Ikena Oncology, Inc. (-1.24),

Build a custom stock screener for Genelux Corporation (GNLX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Genelux Corporation using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Genelux Corporation (GNLX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Genelux Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.